ReviewBiomedicines2023
DNA Gyrase as a Target for Quinolones.
Review in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 129 citations in OpenAlex.
- Bactericidal activity of silver nanoparticles in drug-resistant bacteria.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Pooled it
- Computational introspection of impact of mutation A90V and A90E in DNA gyrase a of Mycobacterium tuberculosis in developing resistance against Delafloxacin.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- In Silico and In Vitro Evaluation of Atriplex halimus: Antibacterial Activity, Molecular Docking, ADMET Profiling, and Cytotoxicity Assessment.Chemistry & biodiversity · 2026Article
- Two Novel 1,4-Naphthoquinone Derivatives as Potent Agents Against Multidrug-Resistant Staphylococcus aureus and Pathogenic Gram-Positive Bacteria.Drug development research · 2026Article
- 2-Quinolone-1,2,3-triazole-benzofuran-N-acylhydrazone hybrids as antiviral and antimicrobial agents: synthesis, in vitro screening and molecular modeling.Molecular diversity · 2026Article
- Gemifloxacin resistance inMicrobiology spectrum · 2026Article
- Dual-Peptide Nanoplatform: Mesoporous Silica Nanoparticles Functionalized With a Cell-Penetrating Peptide and Loaded With Rationally Designed Antimicrobial Peptides for Tuberculosis Therapy.Advanced healthcare materials · 2026Article
- Antimicrobial and Nutritional Properties of Edible Oyster Mushroom (Food science & nutrition · 2026Article
- Antioxidant and Antibacterial Activities of Secondary Metabolites Produced by Streptomyces Isolates Against Extended-Spectrum β-Lactamase-Producing Bacteria.MicrobiologyOpen · 2026Article
- Structural and Computational Analysis ofBiomolecules · 2026Article
- Fluoroquinolone Resistance Patterns in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Structural elucidation, biological significance and computational approach of Copper(ii), Nickel(ii) and Cobalt(ii) with bidentate schiff base of N-(Napthalene-1-ylmethylene)isonicotinohydrazide.Scientific reports · 2026Article
- Benzimidazole-Quinoline Hybrids: Synthesis and Antimicrobial Properties.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Indolizinoquinolinedione Metal Complexes: Structural Characterization, In Vitro Antibacterial, and In Silico Studies.Molecules (Basel, Switzerland) · 2026Article
- Spectrochemical, medicinal, and toxicological studies of moxifloxacin and its novel analogs: a quantum chemistry and drug discovery approach.RSC advances · 2026Article
- Preserving fermented-foods microbial diversity through systematic culturomics for the discovery of multi-strain probiotic candidates.Current research in food science · 2026Article
- Quinoline Heterocyclic Clubbed Hydrazone Derivatives as Potential Inhibitors of MutantCurrent medicinal chemistry · 2026Article
- A comparative study of wound healing kinetics, efficacy, and profiling of VG111 in canine wounds.Frontiers in veterinary science · 2026Article
- Design, Synthesis, and Biological Evaluation ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Structural and Computational Analysis ofbioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial DNA gyrase is a type II topoisomerase that can introduce negative supercoils to DNA substrates and is a clinically-relevant target for the development of new antibacterials. DNA gyrase is one of the primary targets of quinolones, broad-spectrum antibacterial agents and are used as a first-line drug for various types of infections. However, currently used quinolones are becoming less effective due to drug resistance. Common resistance comes in the form of mutation in enzyme targets, with this type being the most clinically relevant. Additional mechanisms, conducive to quinolone resistance, are arbitrated by chromosomal mutations and/or plasmid-gene uptake that can alter quinolone cellular concentration and interaction with the target, or affect drug metabolism. Significant synthetic strategies have been employed to modify the quinolone scaffold and/or develop novel quinolones to overcome the resistance problem. This review discusses the development of quinolone antibiotics targeting DNA gyrase to overcome bacterial resistance and reduce toxicity. Moreover, structural activity relationship (SAR) data included in this review could be useful for the development of future generations of quinolone antibiotics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.